Inhibition of ADAM-17 more effectively down-regulates the Notch pathway than that of γ-secretase in renal carcinoma

Table 1 Expression of ADAM-17 in renal carcinoma tissues

Pathological factors	n	ADAM-17 positive	ADAM-17 negative	χ ²	P
TNM stage				16.39	<0.01
I	14	3	11
II	22	14	8
III	25	21	4
IV	6	5	1
Rate		64.18%	35.82%

64.18% of positive expression of ADAM-17 was recorded in all 67 cases of renal carcinoma tissues, there are 26 positive cases in stage-III and stage-IV renal carcinoma and 5 negative cases, which indicates that ADAM-17 expression is more in high stages of RCC; despite the low expression rate in stage-I renal carcinoma, the ADAM-17 expression is increased as the tumor stage increasing(χ²=16.39, P<0.01).

ISSN: 1756-9966